MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:27Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Biguanides]]
			[[Category:Antihyperglycemic agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #2

2026-05-23T03:25:35Z

parser-claude batch MedTemplate pre-fill, Top 300 #2

New page

{{MedTemplate
| generic = Metformin
| brand = Glucophage, Glucophage XR, Fortamet, Glumetza, Riomet
| structure =
| classes = [[:Category:Biguanides|Biguanide]], [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]]
| uses = <vote slug="type2-diabetes-use">Type 2 diabetes mellitus</vote>, <vote slug="prediabetes-use">Prediabetes</vote>, <vote slug="pcos-use">Polycystic ovary syndrome</vote>
| starting_dose = 500 mg PO once or twice daily with meals; titrate weekly to limit GI effects
| preparations = 500 mg, 850 mg, 1000 mg IR tablets; 500 mg, 750 mg, 1000 mg ER tablets; 500 mg/5 mL oral solution
| fda_max = 2550 mg/d (IR); 2000 mg/d (ER)
| pill_id =
| routes = Oral
| onset = Glucose lowering within days; HbA1c effect at 8-12 weeks
| duration = ~12 hours (IR); 24 hours (ER)
| halflife = 6.2 hours (plasma); ~17 hours in erythrocytes<ref name="glucophage-label">FDA Prescribing Information, Glucophage (metformin HCl), Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf</ref>
| bioavailability = 50-60% (oral; decreased with food, but food given anyway for GI tolerance)<ref name="glucophage-label" />
| pregnancy = Generally considered safe; widely used in PCOS and gestational diabetes; placental transfer occurs.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="metformin-mech-claim">Metformin activates AMPK and suppresses hepatic gluconeogenesis, with secondary effects on intestinal glucose absorption and the gut microbiome.</vote> Does not stimulate insulin secretion; minimal hypoglycemia risk as monotherapy. Cleared renally unchanged; dose-adjust by eGFR<ref name="glucophage-label" />. Rare lactic acidosis primarily in renal failure or acute illness.
}}

== References ==
<references />

Metformin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #2